TY - JOUR
T1 - Resistance of candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with aids
T2 - Documentation by in vitro susceptibility testing and dna subtype analysis
AU - Redding, S.
AU - Smith, J.
AU - Farinacci, G.
AU - Rinaldi, M.
AU - Fothergill, A.
AU - Rhine-Chalberg, J.
AU - Pfaller, M.
N1 - Funding Information:
Received 13 April 1993; revised 21 June 1993. Informed consent was obtained from the patient, and guidelines for human experimentation of the U.S. Department of Health and Human Services and those of the authors' institutions were followed in the conduct of the clinical research. Financial support: This study was supported in part by the Roerig Division of Pfizer, Inc. Reprints or correspondence: Dr. Spencer Redding, Dental Dean's Office, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284.
PY - 1994/2
Y1 - 1994/2
N2 - We describe a patient with recurrent episodes of oropharyngeal candidiasis who required progressively higher doses of fluconazole to control the infection. The patient was treated for 14 infections over a 2-year period with doses of fluconazole that ranged from 100 to 800 mg per day. Clinical response, two methods of in vitro susceptibility testing, and molecular epidemiologic techniques were evaluated for 12 of the 14 episodes. Ultimately, the patient became unresponsive clinically to a dose of 800 mg of fluconazole per day. In vitro susceptibility testing of isolates obtained during these successive episodes of infection revealed the development of resistance to fluconazole, and molecular epidemiologic techniques confirmed the persistence of the same Candida albicans strain throughout all 12 episodes.
AB - We describe a patient with recurrent episodes of oropharyngeal candidiasis who required progressively higher doses of fluconazole to control the infection. The patient was treated for 14 infections over a 2-year period with doses of fluconazole that ranged from 100 to 800 mg per day. Clinical response, two methods of in vitro susceptibility testing, and molecular epidemiologic techniques were evaluated for 12 of the 14 episodes. Ultimately, the patient became unresponsive clinically to a dose of 800 mg of fluconazole per day. In vitro susceptibility testing of isolates obtained during these successive episodes of infection revealed the development of resistance to fluconazole, and molecular epidemiologic techniques confirmed the persistence of the same Candida albicans strain throughout all 12 episodes.
UR - http://www.scopus.com/inward/record.url?scp=0028006489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028006489&partnerID=8YFLogxK
U2 - 10.1093/clinids/18.2.240
DO - 10.1093/clinids/18.2.240
M3 - Article
C2 - 8161633
AN - SCOPUS:0028006489
VL - 18
SP - 240
EP - 242
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 2
ER -